Thank you, operator. Good morning, and welcome to Medtronic’s second quarter conference call and webcast.

During the next hour, Omar Ishrak, Medtronic chairman and chief executive officer; and Gary Ellis, Medtronic’s chief financial officer; will provide comments on the results of our fiscal year 2014 second quarter, which ended October 25, 2013. After our prepared remarks, we’ll be happy to take your questions.

First, a few logistical comments. Earlier this morning, we issued a press release containing our financial statements and a revenue by business summary.

You should also note that some of the statements made during this call maybe considered forward-looking statements and that actual results might differ materially from those projected in any forward-looking statement. Additional information concerning factors that could cause actual results to differ is contained in our periodic reports filed with the SEC.

Therefore, we do not undertake to update any forward-looking statement. In addition, the reconciliations of any non-GAAP financial measures are available on the Investors portion of our website at medtronic.com.

Finally, unless we say otherwise, references to quarterly results increasing or decreasing are in comparison to the second quarter and full year 2013, and all year-over-year revenue growth rates are given on a constant currency basis. With that, I am now pleased to turn the call over to Medtronic chairman and chief executive officer, Omar Ishrak.

Good morning, and thank you, Jeff. And thank you to everyone for joining us today.

This morning we reported second quarter revenue of $4.2 billion and non-GAAP diluted earnings per share of $0.91, both representing growth of 3%. Our Q2 revenue growth was in line with our outlook for the year, and we are performing at or better than the market in almost every one of our business lines.

Q2 also represents another quarter where our overall organization delivered balanced growth with strong performances in some areas offsetting challenges in other parts of our business. Looking ahead, we are confident that our three primary strategies: therapy, innovation, and globalization in economic value will position us well to thrive in the transforming healthcare environment.

This quarter, we made significant progress on a number of new therapy growth drivers that we intend to launch over the coming quarters. These, combined with our continued focus on globalization and economic value, will not only help us improve our competitive position and overall growth profile but will also further strengthen and geographically diversify our business, allowing us to reliably deliver consistent growth.

As you will recall, in Q1 I discussed the three specific challenges that negatively affected our growth and that we believed would improve going forward: U.S. diabetes, U.S.

PAINSTIM, and U.S. ICDs.

I am pleased to report that we have made significant progress in all three businesses. First, in the U.S.

diabetes, we received FDA approval in late September for our MiniMed 530G system, several months earlier than we estimated in August. Our diabetes team executed well, ramping up manufacturing in a short period of time to start shipping in mid-October.

While we are still somewhat supply constrained as we transition our full manufacturing to Puerto Rico, early signs are that the 530G system is going to be a big success in the market, and we expect our U.S. diabetes business to grow in the mid-teens and contribute approximately 100 basis points to overall Medtronic growth in the back half of the fiscal year.

Second, in U.S. PAINSTIM, you will recall that we received FDA approval for our innovative MRI SureScan spinal cord stimulator much earlier than expected.

While this resulted in the supply constraints last quarter, and for the first two months of Q2, our neuro team diligently worked through these issues and is now executing the full product launch. The early response from the market is impressive.

U.S. PAINSTIM grew in the mid-teens in the final month of the quarter and we expect this level of growth to continue, contributing roughly 40 basis points to overall Medtronic growth in the second half of the year.

Third, in U.S. ICD, you will recall that our Q1 results were affected by lower levels of wholesales because of the [phase in] timing of our new high powered products, which, as you anticipated, resolved itself in Q2.

Customers continue to adopt our latest generation devices, Viva and Evera, helping us, by our estimation, to gain share sequentially. Equally important, our ICD prices, which has been down in the low to mid single digits for several quarters, was actually flat in Q2, based on the strength of our latest generation devices.

In addition to these improved performances, surgical technologies delivered another outstanding quarter, growing 11%. All three of these businesses, ENT, neurosurgery, and advanced energy, continue to execute and deliver solid growth.

In particular, I’d like to recognize advanced energy, which grew over 20% again this quarter. This is becoming a very important business for us, with cross-selling opportunities in spine, ortho, and CRDM.

Advanced energy was formed from the first two acquisitions at the beginning of my tenure as CEO, and the business has been delivering strong double-digit growth in the five consecutive quarters since the first anniversary of these acquisitions. These results illustrate that when we combine diligent strategic rationale, strong integration plans, and solid execution, we can generate significant returns on investment.

In Q2, our organization delivered on the bottom line, despite multiple pressures. The most significant departure from expectations was in our gross margin.

It is important to note, though, that pricing was in line with expectations and did not affect our Q2 gross margin performance. Instead, we can point to three distinct issues.

First, FX pressure negatively affected the gross margin by 50 basis points. Second, the manufacturing ramp of a number of new products caused higher levels of scrap and obsolescence, which had a negative impact of 20 basis points.

And third, as we mentioned last quarter, we aggressively continued to reallocate engineering resources to promptly and comprehensively address the specific quality issues outlined in our neuromodulation and diabetes warning letters. This resulted in a shift of spending from R&D to cost of goods sold, thereby negatively affecting our Q2 gross margin by 40 basis points.

While diverting these resources is costly, ensuring the highest level of quality and regulatory compliance has, and always will be, a personal priority for me and the central focus of everything that we do at Medtronic. In the first half of our fiscal year, we generated over $1.8 billion of free cash flow, and over the next five years, we expect to generate over $25 billion of free cash flow.

Our organization remains focused on improving our already robust levels of free cash flow generation. For example, we continue to make progress on our working capital improvement program, with the goal of increasing our inventory turns by 50% by FY17.

We’re committed to returning 50% of our free cash flow to our shareholders through dividends and share repurchases, a commitment level we believe is appropriate given our current mix of U.S. and international free cash flow.

As you know, this mix continues to be constrained by U.S. tax policy, which creates a negative incentive for us to repatriate cash to the U.S.

The remaining 50% gives us the flexibility to make the necessary investments for sustainable growth. We continue to be very disciplined in how we deploy our capital, with a strong focus on returns.

Our potential M&A transactions must not only be strategically aligned, but they must also stand up to the high standards of growth, surpassing our mid-teens risk-adjusted hurdle rate, as well as minimizing the diluted impact of shareholder EPS growth expectations. As we look ahead, we not only have a number of near and mid-term growth opportunities, but we also have some challenges to overcome.

First, in Japan, our team has done an incredible job guiding growth over the past four quarters and the strength of product launches in our cardiac ambassador group. However, we will now be facing a period of difficult year over year comparisons from these product launches, as well as the biennial [unintelligible] zone pricing adjustments that are anticipated to go into effect in April.

As a result, Japan, which contributed significantly to our total company growth in the first half of fiscal year is now expected to have closer to flat growth in the second half. Next, our BMC business continues to be challenged, in Q2, this business declined 17%, which is worse than we were expecting.

We continue to stand behind this product based on its safety and efficacy profile and improved limitations. However, the product remains under pressure as some surgeons continue the reduce the usage through both patient selection and the use of smaller kits.

We continue to analyze the key drivers behind the customer purchasing decisions, post [unintelligible], and we are urgently examining initiatives to optimize the strengths of BMP in both the U.S. and international markets.

However, given that BMC has yet to show signs of stabilization, if current revenue trends continue for the remainder of the fiscal year, BMC revenue would decline in the midteens for FY14, similar to the decline we experienced in FY13. Finally, our emerging market growth in Q2 was 13%.

While this performance is respectable, and these markets continue to contribute a large portion of our overall company growth, our overall results this quarter were well short of our targeted levels. Across our emerging market regions, there have been a number of region-specific challenges, including product registration issues and distributor conversions, which have held back our growth.

We experienced overall slower growth this quarter, with the largest sequential slowing occurring in Greater China and Central and Eastern Europe. In Greater China, our results were affected by the phase-in of new CRDM products, the discontinuation of the distributor relationship in CBG, and slower overall markets in CRDM in orthopedics.

In Central and Eastern Europe, this has been tracking above 20% in eight of the last nine quarters. Growth was in the midteens in Q2, primarily due to Russia, where slowing GDP growth, along with some major fiscal funding constraints, are negatively affecting healthcare budgets.

Looking at emerging markets in total, I realize that over the past few quarters our growth rates have modestly slowed. However, the fundamental demand in the end markets remains strong, and we have several initiatives in place to capitalize on these opportunities.

We remain confident that growth rates will improve and that emerging markets represent a significant long term opportunity. As we look into the future, we’re convinced that our three strategic priorities: therapy innovation, globalization, and economic value, will position us well to thrive in the transforming healthcare environment.

I’d like to update you on each of these strategies. Starting with therapy innovation, it is important to note that Medtronic’s ability to create innovative therapies and new markets is fundamental to our overall growth strategy.

It is a strategy that is deeply rooted in our culture, one that we’re extremely proud of, and an area where we have a proven track record of executing. As we look ahead, we’re on the verge of bringing a number of new therapies to market over the coming quarters.

In addition to our recently launched Viva CRT-D, Evera ICD, and Advisa MRI pacemaker products, the CRDM business intends to launch the Reveal Linq in Q4. This is our next generation implantable loop recorder, which will further expand our footprint upstream in cardiac diagnostics.

In spine, we continue to work with the FDA to bring our next generation cervical disc, the [unintelligible], to the U.S. market.

And we expect to follow that launch with a series of cervical plate launches in FY15. In neuromodulation, the PAINSTIM business will build upon the U.S.

launch of the RestoreSensor MRI by continuing its global rollout with the Q3 launch in Japan. In surgical technologies, we are developing a full pipeline of new power imaging and navigation equipment that improve the economic value proposition for hospitals.

In diabetes, in addition to the ongoing U.S. launch of the MiniMed 530G system with the Enlite sensor, our next-generation insulin pump system, the MiniMed 640G, remains on track for launch by the end of the fiscal year.

And finally, we’re making excellent progress on three fundamentally new therapy areas that meaningfully impact our outlook for FY15 and beyond: our CoreValve transcatheter aortic valve, our Symplicity Flex renal denervation system for treatment resistant hypertension, and our IN.PACT drug eluting balloon. All three of these products are market leaders in Europe, and we are planning to launch all of them in the U.S.

over the coming quarters. CoreValve for extreme risk patients is now expected to launch late this fiscal year, CoreValve for high risk patients in mid-FY15, Symplicity Flex in late FY15, and IN.PACT Admiral in early FY16.

Suffice it to say, we have set ourselves up to deliver what is arguably one of the strongest launch [unintelligible] of innovative therapies in our industry, and while innovative therapies are central to our success and will fuel our growth in our industry for decades, they are no longer enough. In order to unlock the full potential of medtech in the transforming healthcare environment, we are taking meaningful action in the areas of globalization and economic value.

We believe successful execution in both of these areas will position us to win in the changing healthcare marketplace and will be instrumental in establishing durability in our long term performance while creating potential upside to our baseline expectations. With globalization, the key to sustainable growth in emerging markets will be addressing the barriers of access to lifesaving medical technology.

We’ve had teams in place for several quarters focused on identifying local opportunities in all of our geographies to remove the barriers to awareness and training. In CBG, programs like Healthy Heart for All are generating results.

In RTG, we have four spine product development offices set up and running in Europe, China, Japan, and India focused on adapting spine products for the local market. Additionally, in China, we developed [unintelligible], a cranial plating system that in 18 months went from design in Shanghai to manufacturing in [unintelligible] and is now being launched by our surgical technology sales force under the Kanghui brand.

While this is a small product line, it is symbolic of the type of local innovation we want to do across all of our businesses. Likewise, our organization is focused on incorporating economic value into all functions, businesses, and geographies.

We are collaborating with a broader set of stakeholders in developing new business models that deliver economic value to these stakeholders. Essentially, we are moving from being accountable for a product to being accountable for an outcome.

The industry is still early in this process, but we are leading this effort and have started it in two [unintelligible] areas where we can immediately offer solutions for healthcare systems around the world: disease management and hospital efficiency. In disease management, integration activities of our Cardiocom acquisition are progressing well.

With Cardiocom, we intend to pair our existing market leading therapies with a set of complementary services and technology solutions to more effectively treat broader patient populations across the care continuum. These services and solutions offer benefits that are particularly compelling to the broader set of healthcare decision makers, including governments, payers, and hospital systems.

One such solution that Cardiocom is developing is called [RE 30], an cost-effective 30-day readmission reduction program that is focused on minimizing heart failure readmission penalties, which hospitals in the U.S. are increasingly focused on trying to address.

Another area where we are exploring solutions for healthcare systems is hospital efficiency. And this has led to the formation of our new hospital solutions business in Europe.

Hospital solutions is a unique service offering, whereby we enter into long term contracts with hospitals to upgrade and more effectively manage their cath lab and hybrid operating rooms. This is expected to result in wins for all stakeholders.

The hospital sees an improvement in cath lab efficiency and profitability, physicians get access to the latest technologies that can lead to better patient outcomes, and Medtronic benefits not only through the increased use of our technology, but also through incremental service revenue, reduced pricing pressure, better inventory management, and more efficient use of our service personnel. While it is still early, we already have five accounts in the long term contracts for cath lab managed services, representing approximately $300 million in revenue over a seven-year time horizon.

We are particularly encouraged by the positive reaction in the market to our offering and have built a solid pipeline of potential deals. Ultimately, medical technology has the potential to transform healthcare, from being a cost burden for most societies today to an economic driver.

Nations can achieve a long term economic advantage by utilizing medical technology to more effectively and efficiently restore health to the sick and manage chronic disease to keep their populations healthy, allowing more people to be contributing members to society. While we realize this opportunity will certainly be a big challenge, it is one where Medtronic has the capabilities and the intention to lead.

Our market-leading products, in-hospital footprint, healthcare economics expertise, Lean Sigma resources, and financial strength give us unprecedented breadth, global reach, and scale, allowing us to offer broad, valuable solutions. We are determined to transform Medtronic from being primarily a device provider today into the premier global medical technology solutions partner of tomorrow.

Let me now ask Gary to take you through a more detailed look at our results before we take your questions.

Thanks, Omar. Second quarter revenue of $4.194 billion increased 2.4%, as reported, or 3.3% on a constant currency basis, after adjusting for a $38 million unfavorable impact of foreign currency.

Q2 revenue results by region were as follows. Growth rate in the Middle East and Africa was 21%.

Central and Eastern Europe grew 14%. Growth in Greater China was 11%.

Latin America grew 10%. Growth in Japan was 8%.

South Asia grew 6%, and the growth in other Asia Pacific was 4%. The U.S.

grew 2%, and growth in Western Europe and Canada was 1%. Emerging markets grew a combined 13% in Q2 and represented 12% of our total sales mix.

Q2 diluted earnings per share on a non-GAAP basis were $0.91, an increase of 3.4%. Q2 GAAP diluted earnings per share were $0.89, an increase of 41%.

This quarter’s non-GAAP pretax adjustments included a $24 million certain litigation charge related to two previously disclosed government investigations in our CRDM and diabetes business, as well as patent litigation in our coronary business. In our cardiac ambassador group, revenue of $2.199 billion grew 4%, with all businesses contributing to growth.

CRDM revenue of $1.273 billion grew 5%, which included $11 million from our recent acquisition of Cardiocom that was recognized in our AF and Other revenue line. Worldwide ICD revenue of $713 million grew 4%.

We estimate that both the global and U.S. ICD markets grew 3%.

If you look at the first half of our fiscal year, we estimate both the global and U.S. ICD markets grew 1%, which is encouraging and reflects continued stability.

In addition, we estimate we gained a point of ICD share in international markets and we held share in the U.S. in this time period.

Our top technology tiers are now significantly differentiated in the marketplace. Both Viva and Evera feature enhanced shock reduction algorithms, including our proprietary lead integrity alert, which the FDA recently approved for monitoring competitors’ defibrillation leads when connected to our devices.

Our Viva CRT-D also has a proprietary adaptive CRT algorithm which has been clinically proven to improve CRT response rates, resulting in a reduction in heart failure hospitalizations. In addition, in a late-breaking clinical trial at the Heart Failure Society of America meeting in September, adaptive CRT technology was shown to reduce the risk of AF in heart failure patients by nearly 50%.

Both Viva and Evera also have battery and capacitor design improvements to extend our industry leading device longevity. Pacing revenue of $477 million grew 2%, outperforming the global market by nearly 200 basis points.

In the U.S., pacing declined 1% year over year as we continue to see the trend of stabilization in this business. The Advisa MRI pacemaker continues to drive share gains in the U.S.

on both a sequential and year over year basis. In a late-breaking clinical trial at the American Heart Association yesterday, results from the Minerva trial were presented, which showed in a large trial of over 1,000 patients, with sinus node dysfunction and a history of atrial tachycardias, that our proprietary pacemaker features, MDP and reactive ADP, significantly slowed the progression to permanent atrial fibrillation by 61% compared to patients with standard pacemakers.

Looking ahead, assuming stabilization continues in the back half of our fiscal year, U.S. pacing would add approximately 30 to 40 basis points to overall Medtronic growth in FY14 compared to FY13.

AF solutions grew in the midteens, as we continue to gain share in the AF market, driven by our Arctic Front advanced cryoballoon system, which grew over 20%. Customers continue to adopt the second generation system due to its more efficient, safe, and effective treatment for paroxysmal AF.

Looking ahead, we intend to launch our next-gen phased RF product, PVAC Gold, in Europe before the end of the fiscal year. Coronary revenue of $427 million grew 1%.

Globalized ES revenue in the quarter was $274 million, including $103 million in the U.S. and $25 million in Japan.

While GES pricing remains under pressure, we continue to gain the ES share on a sequential and year over year basis, both globally and in the U.S. Our Resolute Integrity’s deliverability, positive data regarding early dual antiplatelet therapy interruption, and unique FDA labeling for diabetes and long term clinical performance is receiving strong customer acceptance globally, despite competitive product launches and next-generation products.

In renal denervation, while revenue continues to be modest, we are investing in developing referral networks, reimbursement, technology development, and clinical and economic evidence to further strengthen our leadership position for this large long term opportunity in hypertension. We are anticipating the full launch of our next-generation Symplicity spiral multi-electrode catheter before the end of the fiscal year.

On the clinical front, we enrolled our first patient earlier this month in our Symplicity HTN-4 trial, which is focused on expanding the indication to include uncontrolled hypertension patients with a systolic pressure between 140 and 160 mmHg. We expect the results of the HTN-3 U.S.

pivotal study to be presented this coming spring. In structural heart, revenue of $281 million increased 4%, driven by strong growth in our transcatheter valve franchise.

We had an outstanding showing at [unintelligible] where data for our CoreValve U.S. pivotal trial for extreme risk patients were presented.

The trial met its primary and secondary endpoints, and the results were exceptionally positive, with a low rate of major stroke, low rate of aortic regurgitations that improved over time, and no association of mild or moderate residual paravalvular leaks or late mortality. The FDA decided it will conduct separate reviews for the extreme and high risk studies and have also determined that no panel review is necessary for extreme risk approval.

Given these developments, we now expect U.S. approval of CoreValve for extreme risk patients by the end of the fiscal year.

For high risk patients, we continue to expect FDA approval in mid-FY15. We have also started our CoreValve Evolut R study of our next-generation recapturable [TAVI] system that features the [Envail] in-line sheath, a 14-French equivalent delivery system.

On the CoreValve renal front, while our Q2 results were affected by the injunction of CoreValve in Germany, we were pleased that the higher German court ordered the discontinuation of the injunction last week. Our German customers were elated to learn that they would once again have access to our differentiated transfemoral technology with our unique valve sizes, catheter sizes, and indications for use options.

In endovascular, revenue of $218 million grew 5%, with solid growth in both our aortic and peripheral businesses. In our aortic business, we grew our AAA share sequentially, both in the U.S.

and globally, on the strength of our market-leading Endurant II stent graft. Our thoracic product line posted double-digit growth as our Valiant Captivia stent graft is gaining broad adoption.

In our peripheral business, we received FDA approval for an extended indication for our Complete SE vascular stent, which is now approved for the use in the SFA and PPA in the upper leg. It is also worth noting that we divested our Pioneer Plus re-entry catheter product line, which represented $11 million of sales over the past year.

Now turning to our restorative therapies group, revenue of $1.602 billion grew 2%. Results were driven by growth in surgical technologies and neuromodulation, partially offset by declines in spine.

Spine revenue of $746 million declined 3%. Core spine revenue of $636 million, which includes [BKP], declined 1%.

The U.S. cores spine market continues to decline in the low single digits, with flat procedural volumes and positive mix, partially offsetting price declines.

Excluding BKP, our core spine business was flat globally and declined 1% in the U.S., relatively in line with the overall market. However, our core spine results were below our expectations as certain underperforming product lines offset the positive momentum that has been building from our new product and procedural innovations.

Our thoracolumbar, cervical, and other biologic product lines all grew this quarter, both globally and in the U.S., driven by our procedural innovation and new technologies. Cervical, in particular, had a solid quarter, with product line extensions to our Vertex platform, as well as our new Bryan artificial cervical disc, contributing to growth.

Our spine business is also increasingly differentiating itself from the competition through enabling technologies that we leverage from our cervical technologies business, including O-arm imaging, StealthStation navigation, and Powerease powered surgical instruments. Hospitals are investing in our capital equipment for spine and surgery as they see clear value from improved surgical precision and more efficient procedures.

And this is resulting in increased revenue for our spinal implants as well as solid growth of capital equipment sales in our surgical technologies business. In fact, we are seeing core spine growth in the upper single digits in accounts that have adopted our O-arm technology.

Outside the U.S., we continue to work on integrating our Kanghui acquisition in China, which is offsetting the lost revenue from our former Weigao joint venture. While there are certainly bright spots in our spine business, we continue to face challenges in other parts of the business, including BMP and BKP, as well as some recent challenges in interbody.

We intend to bolster our interbody product line with the launch of new products including next-generation expandable cages. In BKP, while we did see a sequential improvement, current trends of increased competition continued, and we are working on new products to address this.

Turning to surgical technologies, revenue of $377 million grew 11%, with broad-based growth across all three businesses: ENT, neurosurgery, and advanced energy. ENT grew double digits, with core capital platforms of fusion image guided surgery as well as NIM nerve-monitoring driving growth.

In neurosurgery, capital upgrades of the StealthStation S7 surgical navigation system contributed to another solid quarter. Advanced energy grew over 20% again this quarter, as we continue to see strong adoption of our proprietary [unintelligible] and PEAK PlasmaBlade technologies in the orthopedics, spine, breast, and CRDM replacement markets.

Turning to neuromodulation, revenue of $479 million increased 6% on solid global growth in DBS as well as a strong finish to the quarter in U.S. PAINSTIM.

Our market-leading DBS business delivered another solid quarter, driven by strong client growth in both the U.S. and Western Europe.

The results of our early stim trial, which showed DBS provides superior benefits for patients with early motor complications from Parkinson’s disease is generating significant interest in international markets. In PAINSTIM, while we were supply constrained in the first part of the quarter due to the new product launch, the business did grow double digits in October based on a strong implant growth following the full launch of the RestoreSensor SureScan MRI spinal [unintelligible] system in the U.S.

In gastro uro, while the business continues to grow, it has slowed from its previous double digit run rate due to new therapies entering the market. However, we are confident that InterStim is the most compelling therapy available and while we may continue to see some near term pressure, we expect it to continue as a long term growth driver as its value prevails in the marketplace.

Now turning to our diabetes group, revenue of $393 million grew 3%. We received approval for the MiniMed 530G with the Enlite CGM sensor, and starting shipping to customers late in the quarter.

This is the first system in the U.S. that automatically stops insulin delivery if sensor glucose levels fall below a predetermined threshold, an important step toward our goal of developing a fully automated artificial pancreas.

Multiple peer-reviewed studies have demonstrated the value of our Threshold Suspend feature, including the ASPIRE study and the New England Journal of Medicine, as well as the study out of western Australia that was published in JAMA in September. Every MiniMed 530G pump ships with our new Enlite sensor, which is smaller, more comfortable, and more accurate.

Regarding accuracy, our FDA labeling indicates that Enlite, with its 13.6% overall [mar] is comparable to competitors’ sensors. We have combined these improvements with the Threshold Suspend automation feature of the MiniMed 530G system and we believe we have the best system in the market and will be focused on taking share over the coming quarters.

In addition, we began shipping to customers that had enrolled in our technology guarantee program, which is the trigger for recognizing some of the revenue that we deferred in the prior quarters. As of the end of Q2, we have $27 million of deferred revenue that we expect to recognize over the next two quarters.

Looking ahead, our next-generation pump platform, the MiniMed 640G, remains on track for launch in international markets by the end of the fiscal year. This platform will have a number of innovative features, including a new look and feel, a simplified user interface, and the next step toward a fully automated artificial pancreas, predictive low-glucose suspend.

Now turning to the rest of the income statement, the Q2 gross margin was 74%. As Omar mentioned, there were a number of issues that negatively affected our gross margin this quarter by a combined 110 basis points.

And, compared to last quarter, we recognized an additional $12 million of manufacturing variances, which had a sequential 30 basis point negative impact. However, our standard gross margin was flat year over year as we continue to successfully offset pricing pressure through our five-year, $1.2 billion cost of goods sold reduction program.

Given our ongoing spend to address quality issues, we expect our Q3 gross margin to be in the range of 74.5% to 75% on an operational basis and for a negative FX impact of 40 basis points. For Q4, we expect gross margin to be in the range of 75% to 75.5% on an operational basis.

Second quarter R&D spending of $372 million was 8.9% of revenue. We’ve continued to invest in new technologies and evidence creation to drive future growth.

We expect R&D expense for the remainder of the fiscal year to be in the range of of 8.5% to 9% due to the shifting of R&D resources to enhance our quality systems, which gets recognized under cost of goods sold, as well as tradeoffs we are making to partially offset the U.S. medical device tax.

Second quarter SG&A expenditures of $1.438 billion represented 34.3% of sales. After adjusting for the 10 basis point negative impact from foreign exchange, Q2 SG&A was 34.2%.

We continue to focus on several initiatives to leverage our expenses, although it is worth noting that in Q3 SG&A spending is expected to be modestly higher given the accelerated ramp of our U.S. CoreValve sales force ahead of expected U.S.

approval. In FY14, we would expect to drive 30 to 50 basis points of improvement, which would result in SG&A in the range of 33.8% to 34% on an operational basis.

And it is worth mentioning that we typically see most of our leverage in the fourth quarter. Amortization expense for the quarter was $88 million.

For FY14, we would expect amortization expense to be approximately $85 million to $90 million per quarter. Net other expense for the quarter was $33 million, including net gains from our [unintelligible] about $15 million.

As you know, we hedge the majority of our operating results in developed market currencies to reduce volatility in our earnings from foreign exchange. Based on current exchange rates, we expect FY14 net other expense to be in the range of $190 million to $210 million, which includes an expected $120 million impact from the U.S.

medical device tax. In Q3, we expect net other expense to be in the range of $50 million to $60 million based on current exchange rates.

Net interest expense in the quarter was $33 million. At the end of Q2, we had approximately $12.6 billion in cash and cash equivalents and $12.3 billion in debt.

Based on current rates, we would expect FY14 net interest expense to be in the range of $125 million to $135 million. Our effective tax rate in the second quarter was 19.2%.

Excluding the impact of one-time items, our non-GAAP nominal tax rate in Q2 was 19.4%. For FY14, we expect a non-GAAP nominal tax rate in the range of 19% to 20%.

Our forecast does not assume the U.S. R&D tax credit, which expires on December 31, will be extended.

Currently, the R&D tax credit provides a benefit of approximately $8 million prior quarter. In the first half of FY14, we generated $1.8 billion in free cash flow.

We are committed to returning 50% of our free cash flow to shareholders. In Q2, we paid out $279 million in dividends and we repurchased $713 million of our common stock.

As of the end of Q2, we had remaining authorization to repurchase approximately $68 million. Second quarter average shares outstanding on a diluted basis were 1.009 billion shares.

For the full FY14, we would expect diluted weighted average shares outstanding to be approximately 1.012 billion shares, including 1.010 billion shares in Q3. Our fully diluted share count for the remainder of the year is expected to be higher due to the higher current share price.

However, it is important to note that the cash we received from stock option redemption, which was $249 million in Q2, will also continue to be used to repurchase shares on the open market to partially offset the dilutive impact. These share repurchases are incremental to our commitment to return 50% of our free cash flow to shareholders.

Let me conclude by commenting on our FY14 revenue outlook and earnings per share guidance. Based on the performance through the first half of our fiscal year, we continue to believe that full year constant currency revenue growth of 3% to 4% remains reasonable for FY14.

While we cannot predict the impact of currency movements to give you a sense of FX impact, if the exchange rates would remain similar to yesterday for the remainder of the fiscal year, then our FY14 revenue would be negatively affected by approximately $140 million to $180 million, including a negative $30 million to $50 million impact in Q3. Turning to the guidance on the bottom line, we continue to expect FY14 non-GAAP diluted earnings per share in the range of $3.80 to $3.85, which implies annual earnings per share growth of 6% to 8% on an operational basis, after adjusting for certain tax benefits that we received in FY13 as well as the headwinds from the medical device tax and incremental interest expense in FY14.

As in the past, my comments on guidance do not include any unusual charges or gains that might occur during the fiscal year. I will now turn it back over to Omar, who will conclude our prepared remarks.

Omar?

Thanks, Gary. Before opening the lines for Q&A, let me briefly conclude by noting that over time we are striving to reliably deliver on our baseline expectations, which are consistent mid single digit revenue growth, consistent EPS growth 200 to 400 basis points faster than the revenue, and returning 50% of our free cash flow to shareholders.

As I mentioned earlier, over the coming quarters, we are on the verge of bringing a number of new therapies to market, and we are setting ourselves up to deliver what is arguably one of the strongest launch cadences of innovative therapies in our industry. We believe that crisp execution of both our baseline and long term growth strategies, combined with strong and disciplined capital allocation, will enable us to create long term, dependable value in healthcare.

With that, we would now like to open the phone lines for Q&A. In addition to Gary, I’ve asked Mike Coyle, president of our cardiac and vascular group, and Chris O’Connell, president of our restorative therapies group, to join us again for the Q&A session.

We are rarely able to get to everyone’s questions, so we respectfully request that you limit yourself to only one question, and if necessary one followup, so that we can get to as many people as possible. If you have additional questions, please contact our investor relations team after the call.

Operator, first question please?

If we look at the ICD market growing 3% this quarter, I don’t think any of us really think the ICD market is going to sustain that type of pace, so help us back out, if you would, the stocking impact for you guys that was a negative last quarter that was a positive this quarter, and maybe help us get to what the underlying market is doing. And second, just on the buildout of the field specialists ahead of the U.S.

CoreValve launch, are you assuming in the fourth quarter that you’ll have CoreValve revenues to start to leverage that? It seemed like you were suggesting that you would get some leverage in the fourth quarter.

And does that imply that there will be some revenues there?

Let me start with the ICD market. As you’ll remember, last quarter we talked about the challenge being the new product launches that we had, and trying to get those on contract when we were looking for an ASP increase.

And so that led to some destocking of hospital inventories as we worked through the process in hospitals that have obviously put up some larger barriers to agreement to ASP increases. That worked itself out during the course of the second quarter, and I think you can reasonably assume that basically they’re back to where they are comfortable stocking.

So that now makes it a pretty reasonable picture to just look at the full first half of the year and say, what does the overall growth profile look like? And that’s where we get to this roughly 1% global market growth.

So that, I think, should give you a picture of what we think is happening with the overall market. On the second question, regarding CoreValve, we are not counting on any meaningful revenues coming in the fiscal year, from CoreValve.

And we are going to be obviously ramping our field representation in advance of the launch. So that’s in our current set of assumptions.

Obviously what FDA decides to do in terms of the approval is up to them.

Just to add to what Mike said, the leverage we’re talking about in Q4 is not necessarily coming from CoreValve. It’s just our natural leverage.

If you go back over history, historically in our fourth quarter, because we have more selling days and it’s our strongest quarter, there’s more leverage in that fourth quarter, and that’s what we were referring to.

And then just one followup. Omar, do you want to spend just another minute on China and more broadly the slowdown in emerging markets this quarter and just the confidence in the reacceleration, even if it’s not next quarter or over the next several quarters?

I think this quarter we just happened to have a bunch of different regions slow down. Just by coincidence everything happened together.

We expect this to rapidly start to reaccelerate, because everywhere I go, the fundamental growth drivers are clearly there. There are patients everywhere who need attention from existing therapies.

In addition, we’ve got several very concrete plans in place that will start to sort of deliver real revenue growth over the next few quarters, and we’ll share that with you as they mature. In terms of China itself, I mentioned a few very specific items in terms of distributor conversions and some new products.

And the overall environment there, there’s some noise out there, because of different regulatory type concerns, but in general we don’t have any hard data to support anything. Our teams are still calling for good growth going into the back half of the year.

Question either for Omar or Chris. The core spine, it looks like it declined again.

The comps weren’t that tough. Your next biggest competitor is having integration issues.

You put a lot of money into it, especially focusing on MIS. What parts of the business are underperforming, and why is the big picture thesis you had not coming together quicker?

Let me make one brief comment, and then I’ll let Chris talk to that. You know, we look at all our businesses.

We look at an overall period of time. And if you’ll recall, last quarter we actually had a pretty strong spine performance.

This quarter there were some dynamics, which Chris will talk to, but we’ve got every confidence that, like I mentioned in the commentary, that the cadence of product launches we have in spine actually will deliver over the next few quarters. But I think Chris can answer the question a little more specifically.

I think the spine market, as we’ve talked about in the past, is really bouncing around flat. And our performance has been flat to slightly up in the core spine business and really separating our core spine from the BKP and the BNP business.

I think a lot of the same fundamentals are in place. Maybe the biggest difference this quarter is we had a little less benefit from positive mix, given that we’re in the later stage of our launch cycle on some of the big platforms like Solera.

But overall procedural growth rate is quite flat, and our pricing has been stable, down in the low to mid-single digits. And so this quarter was a little bit softer, particularly in the U.S., and then a couple of countries outside the U.S., namely Germany, Japan, and Latin America.

But the fundamental drivers are still very much there. It is about the product refresh, first of all.

Second of all, it’s about the procedural innovation. We’re getting good uplift from our [unintelligible] program, and our new OLIF procedure.

And then as Gary pointed out, the tailwind from our enabling technologies like surgical navigation, we continue to perform much better in accounts that have O-arm, and continue to see uptake in technologies like PowerEase and the nerve monitoring. So there are a couple of holes in the product line, particularly in the interbody space, and there are a couple of small categories like peek rods and IPDs that remain under pressure.

But overall I think our perspective is it’s a relatively stable situation and we expect that core spine business to be stable into the back half of the year. As pointed out, the BMP and the BKP businesses are both hurting us right now, although the kyphoplasty business does seem to be showing signs of stabilization in the U.S.

and we watch the BMP part closely. So that’s the way I’d characterize it, Matt.

And then just a quick one for Gary. I know you don’t give quarterly guidance.

When you look at the back half of the year, the gross margin in the third quarter is a little lower than the consensus. You’ve got a tough tax comp in the third quarter.

Should we be thinking more about back end loading the second half to the fourth quarter versus the third quarter, since the guidance is unchanged?

Obviously we’re not going to give necessarily quarterly guidance, but I think you’ve highlighted a couple of issues that the market should take into consideration. Our Q3 last year did include some significant tax benefits.

If you factor those out, you’re probably more like at an earnings per share of $0.88, which is kind of similar to where we were last year in Q2. And our Q2 and Q3 tend to be somewhat similar.

We’re pretty close. And so where the consensus is right now on Q3, based on the gross margin issues we highlighted, we think we’ll improve in Q3 and as we go into Q4, but it will be a little bit more in Q3 here, with these quality costs we’ve talked about and the launch of the CoreValve product line.

I wouldn’t be surprised to see people moving a penny or two from the Q3 to our Q4. We’re not changing our full year guidance, and we wouldn’t expect the [unintelligible] to change, but seeing some shift occur from Q3 to Q4 would not be unexpected.

Just a quick one, Gary, just kind of following up on the gross margin. You did, it sounds like, moderate the full year gross margin expectations.

Can you just walk through what the change is for that? Is it just the higher product [unintelligible], or just maybe some of the warning letter charges perhaps coming in a little bit higher?

I think it’s a little bit of all of those factors. First of all, clearly the FX impact on cost of sales has been greater than we probably expected even a quarter ago.

And we just don’t know exactly how that will play out, but it clearly has been a little bit more negative. But the big surprises really were in the situation that as we’ve ramped up all these new product lines, which the good news is we’re getting additional revenue from that.

The bad news is there’s some additional costs in ramping up. You don’t get the initial yields you expect right away, and especially when you’re having to ramp up very, very quickly, the scrap and obsolescence also becomes higher, just due to the fact that, for example, on some of the new products, the older products are no longer as much in demand, so we have a higher obsolescence.

So that’s the good news of having some of these products be [unintelligible] in the marketplace. The bad news is it affects gross margin.

So those, we actually think are a little bit more one-time, and will start to work themselves off after Q2 here with the launches of a lot of these new products. But the quality issues, as you highlighted, we do expect will continue for at least the next quarter or two as we make significant investments in shifting resources from really the R&D efforts up into addressing our quality compliance issues, both in neuro and diabetes.

And so that’s why we pulled things back a little bit. The good news is pricing is actually, if anything, kind of in line with what we expected, maybe even slightly better, and we are offsetting that with the cost reductions we have across our various product lines.

But these one-time other product type costs clearly impacted us more than we expected in Q2, and we’re assuming that that will play a little bit into Q3, and that’s why for the full year we’re down. As we go forward, we would expect those obviously would not be as significant going into next year.

And then just for you, you had commented in your prepared remarks just around the medium-term outlook of getting back into the mid-single digits. And you talked about the number of new products coming.

I guess what is your confidence that - I know you’re not giving guidance for FY15 - but that as we’re exiting out of ’14, you’re well-positioned to kind of get back to that mid single digit growth rate in ’15. Or do you think that maybe some acquisitions might be needed to help get you there?

First, the main comment here is that like I pointed out in the commentary, the number of new products coming out is really unprecedented, at least for the time being and for several years probably before that. And not only Medtronic, but if you look across the industry, that number of products coming out, with that regularity, across the breadth of our businesses, whether you talk about the different businesses in [TVG] or some of the stuff that we do in spine that we think will accelerate growth there.

Or you talk about the [IBT] piece. So if you look across the entirety of our businesses, this is quite a change.

And it’s got to have some impact. And right now, we’re close to mid-single digits.

If you recall, last year we were there, and we’ve had a few quarters here where we’ve had some pressures, but we’re borderline. So I would expect that these launches will help us.

They have to. In addition to that, we’ve got a series of other activities that we’re doing, particularly around globalization, which we expect will also help us.

Having said that, we live in a place where surprises are not uncommon, and markets are still volatile across the world. Healthcare is a big issue in terms of government focus and spending.

And you know, we always have to be a little cautious about where surprises can come from. But on balance, I think our position at this stage is about as good as it’s been since I’ve been here, in terms of future outlook.

Just a few followups here. Gary, I know you’ve had a lot of commentary on gross margins, but if you could go from the second quarter here to the fourth quarter, at the upper end of the range there’s about a 150 basis point improvement.

Just specifically on FX and quality, how much of a contribution are those two factors in that 100-150 basis point improvement heading into the fourth quarter?

Well, the reality is your FX in the fourth quarter is much less than right now. [If the rates] stay where they’re at, and that’s what that’s all based on, the FX impact in the fourth quarter would be relatively minor, and so you pick up almost 40 basis points right there, just through the FX.

The other piece would be the [equality] items that we’re talking about, there will also be some costs occurring in the fourth quarter as we continue to focus on addressing the warning letters. But you’re also having that cost on a much higher revenue number.

And so that’s what also drives your gross margins in the fourth quarter. If you look back historically, the gross margins in the fourth quarter also tend to be at a higher level, as I mentioned, even with the SG&A, because you have a fixed cost that’s on a much higher revenue number.

And so, in general, part of it is just your historical trends. The gross margin is probably 40-50 basis points higher in the fourth quarter.

Part of it is related to FX and part of it is related to the quality cost. Should start to minimize as we go through the fourth quarter itself.

And then Mike, maybe just two broader cardio questions for you. The first, the outlook for your coronary business, considering you do next-generation stent systems in the market, is that a concern for us on volume, or price, or neither?

And then just another question on CoreValve. Should we assume next quarter we see normalized market growth given the inventories?

And if there are any pricing concessions given in Germany, should we assume you can get back to your prior pricing?

We would expect normalization in the German market to take place over the next two quarters, just because of the big volatility that took place over the last two quarters. So I wouldn’t say it will all be back to normal next quarter, but certainly when we get into the fourth quarter I would expect normalization to have occurred.

On the U.S. side, what I’d point out is we’re now six to seven questions into the launch of Resolute Integrity.

We’ve lapped its launch in every major market around the world, and we continue to show share capture. And I think what that’s about is a couple of things.

One is just the performance of the product. The handling of the product, the diabetes labeling, the recent data on [DAPT].

I mean, it’s a great product, and I think the more use it gets, the more physicians are coming to appreciate that. But it also fits very nicely into our broader CVG strategy in that we have moved increasingly toward having Resolute Integrity involved in multi product line bundles across our businesses, which include services and programs in those bundles.

And that product line has been the biggest beneficiary of it. So if you look historically, it used to be when you brought out a new stent product your share would move in the first two or three quarters, and then that would be it.

What we’re seeing is just a continued growth in our share position in DES, and we think it’s because it’s a great product and it’s fitting into a great broader strategy for CVG.

First just a couple of quick questions on the pipeline and the visibility of the pipeline. Just wanted to confirm that the American College of Cardiology meeting will be the place that we’ll probably see the data from your renal denervation trial, the U.S.

trial, as well as the next edition of the CoreValve data. And then also wanted to confirm just that the drug coated balloon data is still on track for showing it in early April at [unintelligible].

Just wanted to confirm those dates.

Those continue to be our operating expectations.

And then I was wondering if you could talk just a little bit more about the ICD market and why it’s improving. Understanding there’s some stocking issues, and you made some comments earlier, but I was just wondering, is this uptick in the market purely a function of a lot of new products in the market for the first time in a while and maybe seeing better pricing?

Or do you actually think there’s been a unit uptick in the ICD market?

We’ve certainly seen stabilization in the initial implants for ICDs, which is a good sign, obviously. Something we’ve been looking for, and have now seen.

On the pricing side, basically it’s flat overall pricing, and we are seeing price increases tied to the new product launches in our high tier, but we continue to see pricing pressure in the mid tier technologies. You net it all out, it’s relatively flat ASPs, which of course is a nice improvement over the 4% to 5% ASP declines we were seeing at this time a year ago.

So generally speaking, it’s market stabilization that we’re seeing.

Omar, I just wanted to ask you quickly about the Cardiocom business, your venture into the disease management space. How should we be looking at that in terms of is it a growth driver?

Is it a service that Medtronic is going to be providing to try and ensure deeper partnerships with hospitals and hospital systems? And how much investment do you need to develop or acquire new technology platforms to really optimize your offering?

And then specifically for the important avenue of heart failure rehospitalization prevention, there’s a potential pulmonary monitoring device going to be approved by the FDA. Can you speak to Medtronic’s views on pulmonary pressure or intracardiac pressure monitoring?

What role will it play in the important market opportunity and how can Medtronic tap into this, and any internal plans to leverage the Cardiocom platform?

Let me give you some perspective. First of all, Cardiocom is an operating business with strong results and strong growth prospects with what it has.

It has some unique capabilities and we’re excited about what they’re doing, and they have strong momentum and growth by themselves. Now, when we take Cardiocom and latch that onto our distribution team, which is far bigger than what Cardiocom had on their own, we obviously open up a lot more opportunities for that business to grow and increase their sales of their existing products.

But in addition to that, the combination of our devices now, going after a more selected patient pool, together with Cardicom’s support services, offer up a future opportunity that is unprecedented, that no other device company and a cardiac monitoring company has ever really got together in this way. And we expect real improvement in growth going forward as a result of that.

Now, with respect to other things that we’re to do, as you know, studies have shown that to move the needle and think like heart failure requires a broad set of services, a broad set of solutions, that have to be executed through multiple stakeholders. We’re in the process of creating that holistic solutions business and leading that effort, and we think Cardiocom is a big asset in that journey.

Other things will certainly be required, but on its own, Cardiocom is an extremely good platform for us to base this journey on. It’s really a long term method.

I’m going to say as well that in terms of the heart failure rehospitalization, we’ve got evidence already that using the Cardiocom capabilities we can have a measurable impact on the reduction of heart failure in specific hospitals, and we think it’s a very cost effective method through which we can achieve that goal. Sensors will be developed over time that will enhance that capability, but in our experience, just doing one thing in an area of that type is usually not enough, but a broad solution is required.

I’ll let Mike comment on specifically the product and technology and his views on that, and maybe our plans.

I think it’s important to look at heart failure as both a short term issue and a long term issue. The short term issue is the 30-day rehospitalization challenge, which all hospitals in the U.S.

agree is something that is a big challenge for them to manage. And that’s where the Cardiocom solution, with this basically very fixed window of time in which to impact, has proven to be very effective.

The alternatives that are being looked at are permanent implants that are very expensive solutions, which really are not the right answer for the short term challenge, but the question would be are they the right solution for the long term challenge of heart failure management. And in that case, clearly as Omar just mentioned, there are a lot of variables involved here.

It’s not just the availability of the measurement from the device, but also the tracking of that data, the specificity and sensitivity of those data, and the cost of managing that information. And we think that’s a very expensive solution that’s being looked at for the long term.

We are really focused on trying to focus in that near term window, not only with Cardiocom, but also with some of the predictive diagnostics that are coming out of our CRDM organization. So you know about Reveal.

We talked about the Reveal Linq, which is the next-generation loop recorder that we have, and there are other predictive diagnostics you’re going to see us talk about over the course of the next six months that we think can be very helpful in managing heart failure patients in that window where there’s a very clear economic need. So that’s how I would characterize our approach to the strategy.

Mike, several questions for you. Firstly, common wisdom is that the [Partner One] indication in the U.S.

is kind of flattening out. As you enter that market, do you see much opportunity for growth prior to indication expansion?

Secondly, I know you guys have had a little sluggishness in enrollings for TAVI, and there’s been talk about extending it to [STS2]. Any progress on that front?

And thirdly, given the joint FDA CMS approval track for renal denervation, how should we be thinking of that uptake in the States now that you have definitive evidence relative to what we’ve seen in Europe?

On the second one, let me just ask Jeff. Do you want to comment?

On [unintelligible] TAVI, we’re talking to the FDA, but there’s really no update on looking more on the enrollment criteria.

First, I think it’s important to point out that what we are seeking approval for in terms of the range of sizes and alternative access routes for CoreValve should significantly expand the number of patients who are going to be candidates for TAVI, because currently the current approved competitive devices are certainly limited in terms of their size and also the invasiveness of a transapical approach. So we think that there is still plenty of opportunity to both take share in the existing segment as well as to expand the number of patients who are getting treated within the extreme risk.

So we’re confident that what we do in terms of our overall expectation for market size continues to be what we would expect to see. On the third question, obviously this is one of the first that’s on the joint track of CMS approval as well as FDA approval.

Our goal would be to have essentially a three month window between those two, the FDA approval and the follow on reimbursement, but again, this is fairly uncharted territory, so we’re going to have to see where that leads, but that’s certainly where we are managing our strategy toward.

And we would expect that obviously, having had data, we’ve always said you have in the data the proven information in the U.S., we think will actually help accelerate the marketplace, and having reimbursement at the same time or close to it would obviously help. So we expect the uptake in the U.S.

would be much faster than what we’ve said outside the U.S.

On CoreValve, can you give us a little more perspective? Mike, do you think you’ve lost share in Germany as a result of the injunction, given what seemed to be some heavy selling into the market in advance of this?

And can we assume that you’re shipping normally now? And just remind me, I think you said you have strong growth in TAVI in Europe.

Can you quantify that more specifically, with a more specific number?

On Germany, obviously if you just look at total revenues that we just reported in the quarter, we lost share on a reported basis, because we had no product that we were able to sell other than for the compassionate use side. But as you may recall from the first quarter, when customers learned that they were going to lose access to this product, there was a lot of demand that basically accelerated purchases.

So in terms of overall share of implants, it’s hard to say, but I don’t think there probably was a lot of share loss in the quarter. And obviously now that we’ll be able to go back into the market with the full offering, I don’t expect there will be going forward.

But it’s going to take a couple of quarters for that to normalize overall.

And on the [unintelligible] side, just as a follow up, is there any way to size to opportunity for the 530G and any sense, of the patients who are getting the devices, are these patients already on a Medtronic pump and upgrading? Are MDI patients converting, or competitor pumps?

Any perspective there would be welcome.

Well, it’s a little early to get too much data on this, because we just started shipping it, but I’ll tell you that the principal response has been outstanding, both from patients who receive the device and just in anticipation of what the product can do. So we’re really confident about the outlook and the general acceptance of this product as we see it.

I think in general most of our Medtronic patients were upgrading at this stage, but we expect some conversions as well. I doubt if there’s going to be too many MDI patients going to this technology first.

But again, it’s very early. We just started shipping this product just about a month or so ago.

So let’s wait and see. But like I said, the anticipation from our patients is very high, and a lot of excitement around it.

Okay, so with that, it’s time to conclude. Thank you all very much for your questions.

And I’d like to briefly note that as you work on filling your 2014 calendars, we plan to host our institutional investor analyst meeting on June 5, which will be held again in New York City. With that, and on behalf of our entire management team, I’d like to thank you again for your continued support and interest in Medtronic.

And for those of you in the U.S., I want to wish you and your family all a very happy Thanksgiving. We look forward to updating you on our progress on our Q3 call, which we anticipate holding on February 18.

Thank you.